Gout, a painful form of inflammatory arthritis, is poised to become significantly more common in the coming decades. Projections indicate that global cases will rise significantly over the next twenty-five years, driven by aging populations, rising obesity rates, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with the disease, and an even larger group—44 million people—have uric acid levels above the normal range, putting them at risk. This looming public health challenge underscores the urgent need for better treatment options.
Current therapies, primarily oral xanthine oxidase inhibitors (XOIs), are effective for many but come with significant drawbacks. Approximately 3% to 5% of patients cannot tolerate them, and they carry boxed warnings for cardiovascular risk. Other side effects include severe gastrointestinal issues, kidney toxicity, and paradoxical initial gout flare-ups that discourage adherence. These limitations leave a substantial portion of patients without satisfactory long-term management, highlighting a clear unmet medical need.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is aiming to fill that gap with XORLO™, a proprietary formulation of oxypurinol. According to the company, XORLO utilizes a liposomal delivery system to overcome the historically poor oral absorption of oxypurinol, enabling effective uric acid reduction at substantially lower total daily doses. This approach is designed to minimize toxic-level exposure and the severe gastrointestinal side effects associated with high-dose traditional therapies. For a deeper look at XORTX, the company’s pipeline and strategy are detailed on its investor page.
The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study is being advanced based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol drug substance—the active ingredient in XORLO—has already begun using XORTX’s proprietary synthetic pathway, and the company is now working with its contract manufacturing partner toward commercial drug batches. These steps are critical for producing GMP-grade clinical supply tablets representative of the intended commercial product.
Regulatory progress is also accelerating. XORTX is working toward a new drug application submission to the FDA, with a new Investigational New Drug (IND) application prepared for submission in the fourth quarter of 2026. The IND describes the clinical development plan for XORLO. If the two-part clinical trial completes successfully, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
The implications of this announcement extend beyond a single company. If XORLO succeeds in clinical trials and gains FDA approval, it could offer a better-tolerated alternative for the millions of gout sufferers who cannot take or struggle with existing XOIs. With the gout population expected to swell, a new option with fewer side effects and improved adherence could meaningfully reduce the burden of this chronic disease on patients, healthcare systems, and economies. XORTX’s progress will be closely watched as a bellwether for innovation in gout management.
This content was originally published on Benzinga. For additional information, readers can view the original release on www.newmediawire.com.
